Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Medios ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

StockNews.com lowered shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating ...

NasdaqGS:NBIX Earnings and Revenue History February 21st 2025 Examining Cashflow Against Neurocrine Biosciences' Earnings. As finance nerds would already know, the accrual ratio f ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...

Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...